ALDX — Aldeyra Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $273.14m
- $213.04m
- 18
- 12
- 88
- 33
Annual income statement for Aldeyra Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 36.4 | 56.2 | 62.7 | 42.8 | 60.1 |
| Operating Profit | -36.4 | -56.2 | -62.7 | -42.8 | -60.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -38 | -57.8 | -62 | -37.5 | -55.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -37.6 | -57.8 | -62 | -37.5 | -55.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -37.6 | -57.8 | -62 | -37.5 | -55.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -37.6 | -57.8 | -62 | -37.5 | -55.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.05 | -1.07 | -1.06 | -0.637 | -0.939 |